Plegridy Real World Observational Program (POP)
Research type
Research Study
Full title
Plegridy™ (peginterferon ß 1a) Real World Effectiveness and Safety Observational Program
IRAS ID
167057
Contact name
Stewart Webb
Contact email
Sponsor organisation
Biogen Idec Limited
Duration of Study in the UK
7 years, 6 months, 19 days
Research summary
This study is being conducted to learn about patients with Multiple Sclerosis (MS) who have been treated with drug called Plegridy (peginterferon ß 1a) . This is a prospective, obervational study with no study drug or medical procedures involved.
Enrolled patients will be followed for a maximum of five years or until patient death, withdrawal, or the patient is considered lost to follow up. All data will be collected by the patients's Neurologist during routine visits or from medical records. Patient-reported outcomes (PROs) will be completed by patients online so there is no need for patients to physically go to the GP clinic to complete questionnaires.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
14/YH/1289
Date of REC Opinion
2 Dec 2014
REC opinion
Favourable Opinion